Microbiotica MB097 Shows Promise in Melanoma Trial
Microbiotica reports positive Phase 1b data for MB097, a precision microbiome co-therapy combined with pembrolizumab in advanced melanoma patients.
Cambridge-based biopharma company Microbiotica has announced positive results from its Phase 1b clinical trial, MELODY-1, evaluating MB097 — a precision microbiome co-therapy — in patients with advanced melanoma. The trial, reported on 18 May 2026, tested MB097 in combination with MSD's anti-PD-1 immunotherapy KEYTRUDA® (pembrolizumab), marking a significant milestone in microbiome UK research and its application to oncology.
Why This Matters for Gut-Cancer Science
The gut microbiome — the vast community of bacteria and other microorganisms living in the digestive tract — is increasingly understood to influence how the immune system responds to cancer therapies. Researchers studying the gut-brain connection and broader microbiome science have long noted that microbial composition affects systemic immunity. In the UK, institutions such as the Wellcome Trust-supported Sanger Institute and the University of Cambridge have been at the forefront of microbiome research, making Cambridge a fitting base for Microbiotica's work. This trial represents one of the first clinical signals that precision microbiome co-therapy can be meaningfully combined with checkpoint immunotherapy.
Phase 1b Findings: A Precision Microbiome Approach
According to Microbiotica, MB097 is an oral live biotherapeutic product (LBP) — meaning it delivers specific, defined bacterial strains directly to the gut. The MELODY-1 Phase 1b trial produced positive results when MB097 was administered alongside pembrolizumab in advanced melanoma patients, per the company's announcement. Microbiotica describes its pipeline as "precision microbiome medicines," reflecting a strategy of targeting the gut's microbial environment with a high degree of specificity rather than using broad-spectrum interventions. The company reports the data support continued clinical development of MB097.
What This Means for UK Patients and Microbiome Research
For health-conscious UK adults following advances in gut health, these findings underscore how intimately the gut microbiome is linked to whole-body health outcomes — including cancer treatment response. While MB097 is not a consumer gut health product, the science reinforces broader NHS and British Dietetic Association messaging about the importance of a diverse, fibre-rich diet in supporting a healthy microbiome. UK patients with advanced melanoma may eventually benefit if MB097 progresses through later-stage trials and regulatory review.
Microbiotica's MELODY-1 results add meaningful clinical weight to a growing body of microbiome UK research suggesting the gut is a viable therapeutic target in oncology. As the gut-brain and gut-immune axes continue to attract scientific attention — from the British Gut Project to UK Biobank studies — precision live biotherapeutics such as MB097 represent a new frontier. The company has signalled it will advance MB097 further, according to its announcement, with the Cambridge-based team continuing to build on these Phase 1b data.
You might also like
- At-Home Gut Test Kits: What UK Users Should Know
- How to Eat an Anti-Inflammatory Diet for Gut Health
- How to Improve Gut Health Naturally in 6 Steps
96 Bacterial Strains. Two Shots a Day.
GOODIE is an award-winning fermented drink with 96 live bacterial strains — more than any yogurt or kombucha — never pasteurised, clinically tested, and 8 in 10 users felt less bloating within 14 days. Curious?